ZNL-0056 is an orally active ATP-competitive inhibitor that targets the EGFR ATP-binding site, specifically Cys797 and Cys775. It selectively inhibits EGFR and its downstream signaling in H3255 cells. ZNL-0056 is applicable for cancer research.
Target:
EGFR
* VAT and and shipping costs not included. Errors and price changes excepted
